TB Matters More

  • Michael J. Selgelid
  • Paul M. Kelly
  • Adrian Sleigh
Part of the International Library of Ethics, Law, and the New Medicine book series (LIME, volume 42)


Tuberculosis (TB) is the second leading infectious cause of mortality worldwide and arguably the most important neglected topic in bioethics. This chapter: (1) explains the ethical importance of TB, (2) documents its neglect in bioethics discourse, (3) maps the terrain of ethical issues associated with TB, and (4) advocates a moderate pluralistic approach to ethical issues associated with TB.


Ethics infectious disease tuberculosis (TB) drug resistance quarantine health care access essential medications justice 


  1. Anand, S., Peter, F., and Sen, A. (eds.) 2004. Public health, ethics, and equity. New York: Oxford University Press.Google Scholar
  2. Balint, J., Philpott, S., Baker, R., and Strosberg, M. (eds.) 2006. Ethics and epidemics. Amsterdam: JAI.Google Scholar
  3. Bates, I., Fenton, C., Gruber, J., Lalloo, D., Medina Lara, A., Squire, S.B., Theobald, S., Thomson, R., and Tolhurst, R. 2004. Vulnerability to malaria, tuberculosis, and HIV/AIDS infection and disease. Part 1: determinants operating at individual and household level. Lancet Infectious Diseases 4(5): 267–277.PubMedCrossRefGoogle Scholar
  4. Bayer, R. and Dupuis, L. 1995. Tuberculosis, public health, and civil liberties. Annual Review of Public Health 16: 307–326.PubMedCrossRefGoogle Scholar
  5. Beauchamp, D.E. and Steinbock, B.S. (eds.) 1999. New ethics for the public’s health. New York: Oxford University Press.Google Scholar
  6. Boseley, S. 2006. Global alert over deadly new TB strains. Guardian. Available at:,329569751-110418,00.html (Accessed 15 May 2007).
  7. Boylan, M. (ed.) 2004. Public health policy and ethics. Dordrecht: Kluwer.Google Scholar
  8. CDC 2006. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs—worldwide, 2000–2004, Morbidity and Mortality Weekly Report 55(11): 301–305.Google Scholar
  9. Cobelens, F.G. 2007. Tuberculosis risks for health care workers in Africa. Available at: – fn1#fn1 Clinical Infectious Diseases 44: 324–326.Google Scholar
  10. Cohen, J.C. and Illingworth, P. 2003. The dilemma of intellectual property rights for pharmaceuticals: the tension between ensuring access of the poor to medicines and committing to international agreements. Developing World Bioethics 3(1): 27–48.PubMedCrossRefGoogle Scholar
  11. Cohen, J.C., Illingworth, P., and Schüklenk, U. (eds.) 2006. The power of pills: social, ethical, and legal issues in drug development, marketing and pricing. London: Pluto.Google Scholar
  12. Coker, R. 2000. Tuberculosis, non-compliance and detention for the public health. Journal of Medical Ethics 26: 157–159.PubMedCrossRefGoogle Scholar
  13. Coker, R. 2003. Asylum and migration working paper 1: migration, public health and compulsory screening for TB and HIV. London: Institute for Public Policy Research.Google Scholar
  14. Coughlin, S.S., Soskolne, C.L., and Goodman, K.W. (eds.) 1998. Case studies in public health ethics. Washington, DC: American Public Health Association.Google Scholar
  15. Dawson, A. and Verweij, M. (eds.) 2007. Ethics, prevention, and public health. Oxford: Oxford University Press.Google Scholar
  16. Democracy Now. 2007. Is sickness a crime? Arizona man with TB locked up indefinitely in solitary confinement. Available at: (Accessed 10 May 2007).
  17. Dye, C., Hosseini, M., and Watt, C. 2007. Did we reach the 2005 targets for tuberculosis control. Bulletin of the World Health Organization, 85: 364–369.PubMedCrossRefGoogle Scholar
  18. Farmer, P. 1999. Infections and inequalities: the modern plagues. Berkeley, CA: University of California Press.Google Scholar
  19. Farmer, P. 2003. Pathologies of power: health, human rights, and the new war on the poor. Berkeley, CA: University of California Press.Google Scholar
  20. Floyd, K. 2007. Global progress towards the TB control targets (with a special attention to TB/HIV and MDR-TB). Presentation at the Stop TB Symposium, 38th World Conference on Lung Health, 8 November, Cape Town, South Africa.Google Scholar
  21. Francis, L.P., Battin, M.P., Jacobson, J.A., Smith, C.B., and Botkin, J. 2005. How infectious disease got left out—and what this omission might have meant for bioethics. Bioethics 19(4): 207–322.CrossRefGoogle Scholar
  22. Francis, L.P., Battin, M.P., Botkin, J., Jacobson, J., and Smith, C. 2006. Infectious disease and the ethics of research: the moral significance of communicability. In Ethics in biomedical research: international perspectives ed. by Hayry, M., Takala, T., and Herissone-Kelly, P. New York: Rodopi.Google Scholar
  23. Gandy, M. and Zumla, A. 2002. The resurgence of disease: social and historical perspectives on the ‘new’ tuberculosis. Social Science and Medicine 55: 385–396.PubMedCrossRefGoogle Scholar
  24. Garrett, L. 2007. The challenge of global health. Foreign Affairs, January/February 2007. Available at: (Accessed 20 February 2007).
  25. Gostin, L.O. (ed.) 2002, Public health law and ethics. Berkeley, CA: University of California Press.Google Scholar
  26. Harries, A. and Dye C. 2006. Tuberculosis. Annals of Tropical Medicine and Parasitology 100(5–6): 415–431.PubMedCrossRefGoogle Scholar
  27. Harris J. and Holm S. 1995. Is there a duty not to infect others? British Medical Journal 311: 1215–1217.PubMedGoogle Scholar
  28. Jackson, S., Sleigh, A.C., Wang, G.J., and Liu, X.L. 2006. Poverty and the economic effects of TB in rural China. International Journal of Tuberculosis and Lung Disease 10(10): 1104–1110.PubMedGoogle Scholar
  29. Kremer, M. and Glennerster, R. 2004. Strong medicine. Princeton, NJ: Princeton University Press.Google Scholar
  30. Lienhardt, C., Ogden, J., and Sow, S. 2003. Rethinking the social context of illness: interdisciplinary approaches to tuberculosis control. In The return of the white plague: global poverty and the ‘new’ tuberculosis ed. by Gandy, M., and Zumla, A. London: Verso.Google Scholar
  31. Lurie, P., and Wolfe, S. 1997. Unethical trials of interventions to reduce perinatal transmission of the Human Immunodeficiency Virus in developing countries. The New England Journal of Medicine 337: 853–856.PubMedCrossRefGoogle Scholar
  32. Ly, T., Selgelid, M.J., and Kerridge, I. 2007. Pandemic and public health controls: toward an equitable compensation system. Journal of Law and Medicine 15(2): 296–302.PubMedGoogle Scholar
  33. MacIntyre, C.R., Plant, A.J., Yung, A., and Streeton, J.A. 1997. Missed opportunities for prevention of tuberculosis in Victoria, Australia. International Journal of Tuberculosis and Lung Disease 1(2): 135–141.PubMedGoogle Scholar
  34. Maloney, S. 2004. National migration health policies: shifting the paradigm from exclusion to inclusion. IOM’s International Dialogue on Migration, seminar on health and migration, Geneva, 9–11 June 2004. Available at: (Accessed 11 May 2007).
  35. Moran, M., Ropars, A.L., Guzman, J., Diaz, J., and Garrison, C. 2005. The new landscape of neglected disease drug development. London: The Wellcome Trust.Google Scholar
  36. MSF, Extensive drug resistant tuberculosis (XDR-TB). 2006. Available at: (Accessed 12 February 2007).
  37. MSF. 2007. No time to wait. Available at: (Accessed 10 February 2007).
  38. Pogge, T. 2005. Human rights and global health: a research program. Metaphilosophy 36(1/2): 182–209.CrossRefGoogle Scholar
  39. Price-Smith, A.T. 2001. The health of nations: infectious disease, environmental change, and their effects on national security and development. Cambridge, MA: MIT Press.Google Scholar
  40. Reid, L. 2005. Diminishing returns? Risk and the duty to care in the SARS epidemic. Bioethics 19(4): 348–361.PubMedCrossRefGoogle Scholar
  41. Resnik, D.A. 2004. The distribution of biomedical research resources and international justice. Developing World Bioethics 4(1): 42–57.PubMedCrossRefGoogle Scholar
  42. Sakoane, R. 2007. XDR-TB in South Africa: back to TB sanatoria perhaps? PLoS Medicine 4(4): e160.PubMedCrossRefGoogle Scholar
  43. Schüklenk, U. and Ashcroft, R.E. 2002. Affordable access to essential medication in developing countries: conflicts between ethical and economic imperatives. Journal of Medicine and Philosophy 27(2): 179–195.PubMedCrossRefGoogle Scholar
  44. Selgelid, M.J. 2005. Ethics and infectious disease. Bioethics 19(3): 272–289.PubMedCrossRefGoogle Scholar
  45. Selgelid, M.J. OnlineEarly 2007. Improving global health: counting reasons why. Developing World Bioethics. Forthcoming in print, doi:10.1111/j.1471–8847.2007.00185.x.Google Scholar
  46. Selgelid, M.J., Battin, M.P., and Smith, C.B. (eds.) 2006. Ethics and infectious disease. Oxford: Blackwell.Google Scholar
  47. Singh, J.A., Upshur, R., and Padayatchi, N. 2007. XDR-TB in South Africa: no time for denial or complacency. PLoS Medicine 4(1): e50.doi:101371/journal.pmed.0040050.PubMedCrossRefGoogle Scholar
  48. Singh, V., Jaiswal, A., Porter, J.D.H., Ogden, J.A., Sarin, R., Sharma, P.P., Arora, V.K., and Jain, R.C. 2002. TB control, poverty, and vulnerability in Delhi, India. Tropical Medicine and International Health 7: 693–700.PubMedCrossRefGoogle Scholar
  49. Smith, C.B., Battin, M.P., Jacobson, J.A., Francis, L.P., Botkin, J.R., Asplund, E.P., Domek, G.J., and Hawkins, B. 2004. Are there characteristics of infectious disease that raise special ethical issues? Developing World Bioethics 4(1): 1–16.PubMedCrossRefGoogle Scholar
  50. Sterckx, S. 2004. Patents and access to drugs in developing countries: An ethical analysis. Developing World Bioethics 4(1): 58–75.PubMedCrossRefGoogle Scholar
  51. Tausig, M., Selgelid, M.J., Subedi, S., and Subedi, J. 2006. Taking sociology seriously: A new approach to the bioethical problems of infectious disease. Sociology of Health and Illness 28(6): 839–849.Google Scholar
  52. UNAIDS. 2007. AIDS epidemic update: December 2007. Available at: (Accessed 4 March 2008).
  53. University of Toronto Joint Centre for Bioethics, Pandemic Influenza Working Group. 2005. Stand on guard for thee: ethical considerations in preparedness planning for pandemic influenza. Available at: (Accessed 15 May 2007).
  54. Verweij, M. 2005. Obligatory precautions against infection. Bioethics 19(4): 323–335.PubMedCrossRefGoogle Scholar
  55. WHO. 2006a. Weekly epidemiological record, September 2006. Available at: (Accessed 10 February 2007).
  56. WHO. 2006b. The stop TB strategy. Geneva, World Health Organization.Google Scholar
  57. WHO. 2007a. Fact sheet no. 104: tuberculosis (revised March 2007). Available at: (Accessed 8 December 2008).
  58. WHO. 2007b. Global tuberculosis control: surveillance, planning, financing. WHO Report. Geneva, World Health Organization. WHO/HTM/TB/2007.376.Google Scholar

Copyright information

© Springer Science + Business Media B.V 2008

Authors and Affiliations

  • Michael J. Selgelid
    • 1
    • 2
  • Paul M. Kelly
    • 3
  • Adrian Sleigh
    • 4
  1. 1.Centre for Applied Philosophy and Public Ethics (CAPPE)Australia
  2. 2.Menzies Centre for Health PolicyAustralian National UniversityAustralia
  3. 3.National Centre for Epidemiology and Population HealthAustralian National UniversityCanberraAustralia
  4. 4.National Centre for Epidemiology and Population Health, ANU College of Medicine and Health SciencesThe Australian National UniversityAustralia

Personalised recommendations